Nanovi Secures Funding for BioXmark™ Injectable Tissue Liquid Marker in Radiotherapy

Raising Radiotherapy Standards and Improving Treatment of Patients With Cancer

Nanovi_LogoCopenhagen, Denmark, — / B3C newswire / – Nanovi is developing products based on advanced biomaterials for use in the treatment of cancer. Nanovi’s first product (BioXmark™) is an injectable tissue liquid marker, used to improve accuracy in the radiation treatment of patients with cancer.

BioXmark™ has the potential to increase radiotherapy quality with minimal changes in today’s procedures and equipment. It will be available for commercial use in Europe around 2015 with clinical data to document its benefit. Continue reading